RBC Capital Keeps Their Buy Rating on Cormedix (CRMD)
In a report released on January 7, Gregory Renza from RBC Capital maintained a Buy rating on Cormedix (CRMD – Research Report), with a price ...
Centerspace price target lowered to $72 from $76 at RBC Capital
RBC Capital analyst Brad Heffern lowered the firm’s price target on Centerspace (CSR) to $72 from $76 and keeps an Outperform ...
EconoTimes1d
RBC Upgrades Utilities Sector While Downgrading Energy
RBC Capital Markets has upgraded the Utilities sector to Overweight, naming it the top defensive sector, while downgrading ...
RBC Capital Keeps Their Buy Rating on Royal Gold (RGLD)
In a report released on January 7, Josh Wolfson from RBC Capital maintained a Buy rating on Royal Gold (RGLD – Research Report), with a price ...
Equity Lifestyle price target lowered to $69 from $72 at RBC Capital
RBC Capital lowered the firm’s price target on Equity Lifestyle (ELS) to $69 from $72 and keeps a Sector Perform rating on ...
Fertilizer market looks stable for 2025, RBC analysts say
Investors in fertilizer equities can expect steady prices and good cash generation, according to analysts at RBC Capital ...
Financial Services Roundup: Market Talk
Find insight on BBVA, Australia’s banks and more in the latest Market Talks covering Financial Services.
Top 30 global stock ideas from RBC Capital Markets analysts
The research team at RBC Capital Markets published their top 30 global stock ideas for 2025, ...
RBC Capital Reaffirms Their Hold Rating on Health Catalyst (HCAT)
In a report released on January 8, Sean Dodge from RBC Capital maintained a Hold rating on Health Catalyst (HCAT – Research Report), with a ...